Pharmaceutical Sector

Pfizer Says New tax rules Cannot Keep it from Shifting Abroad if it Finds the Right Deal

Pfizer Says New tax rules Cannot Keep it from Shifting Abroad if it Finds the Right DealPfizer Inc. America's largest drug manufacturer says that a lucrative deal overseas will not keep it from going in for an inversion.

The US government has put in a lot of effort recently to stop companies from going out of the country due to reduced tax rates abroad. The new rules introduced in the U. S have also made such deals less attractive.

Merck’s Oncology Drug Awarded ‘Breakthrough’ Designation

Merck’s Oncology Drug Awarded ‘Breakthrough’ DesignationThough the third quarter net income for Merck has dropped mainly due to the huge expenditure related to acquisitions and divestitures, yet the drug company's adjusted earnings surpassed the estimates of Wall Street.

FDA priority review for Pfizer breast cancer drug

FDA priority review for Pfizer breast cancer drugPfizer said Monday a trial breast cancer treatment will be given a quickened survey by US controllers, accelerating the methodology for potential regard.

The US Food and Drug Administration has allowed need survey for palbociclib, which would treat certain postmenopausal ladies with cutting edge bosom malignancy, the US pharmaceutical giant said.

Software ‘glitch’ in pharmaceutical world

Software ‘glitch’ in pharmaceutical worldThe unwavering quality of clinical tests used to win regard for a few pharmaceuticals - especially non specific duplicates of unique medications - could be in uncertainty because of a clear programming glitch that may mean information was computed inaccurately.

Salix Plugs Tax Inversion Deal With Cosmo Pharmaceuticals

Salix PharmaceuticalsReportedly, Salix Pharmaceuticals has abandoned the idea of relocating its tax base to Italy. The pharmaceutical company was planning a merger with Cosmo Pharmaceuticals.

The top shareholders of Salix have been reportedly putting pressure on the company since last July when it announced its deal with the Irish subsidiary of Cosmo. The shareholders would like Salix to fix a sales deal with a bigger pharmaceutical firm.

Despite trial, AZ upbeat on benralizumab for COPD

Despite trial, AZ upbeat on benralizumab for COPDAstrazeneca is exceptionally supported about the prospects for benralizumab as a treatment for incessant obstructive pneumonic infection notwithstanding the investigational monoclonal immunizer neglecting to reach its essential endpoint in a Phase IIa trial.

Pages